Syndax Pharmaceuticals, Inc. (SNDX) Shares Sold by Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. lowered its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 0.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 26,499 shares of the company’s stock after selling 95 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.15% of Syndax Pharmaceuticals worth $370,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Airain ltd purchased a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $150,000. Bank of Montreal Can purchased a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $158,000. Alps Advisors Inc. purchased a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $277,000. Trexquant Investment LP purchased a new position in shares of Syndax Pharmaceuticals in the 1st quarter valued at approximately $283,000. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of Syndax Pharmaceuticals by 36.2% in the 1st quarter. TIAA CREF Investment Management LLC now owns 22,924 shares of the company’s stock valued at $315,000 after purchasing an additional 6,091 shares during the period. Institutional investors and hedge funds own 70.68% of the company’s stock.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) opened at 11.90 on Friday. The company’s market cap is $264.41 million. Syndax Pharmaceuticals, Inc. has a 52-week low of $6.31 and a 52-week high of $16.40. The company’s 50-day moving average price is $11.86 and its 200-day moving average price is $11.84.
Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Thursday, August 10th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.09. The company had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.31 million. Syndax Pharmaceuticals had a negative return on equity of 58.23% and a negative net margin of 4,294.59%. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post ($3.11) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/17/syndax-pharmaceuticals-inc-sndx-shares-sold-by-oppenheimer-co-inc.html.
A number of research analysts have recently commented on the company. Instinet restated a “buy” rating and issued a $22.00 target price (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research note on Monday, August 14th. Citigroup Inc. set a $20.00 target price on Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. Nomura lowered their target price on Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 11th. Oppenheimer Holdings, Inc. raised their target price on Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a research note on Friday, August 11th. Finally, Zacks Investment Research upgraded Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating and eleven have given a buy rating to the company’s stock. Syndax Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $23.78.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Stock Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.